Established in 2020 Thursday, May 13, 2021

Gilead Sciences reports almost $900 mn in Q3 remdesivir sales
In this file illustration photo taken on March 25, 2020 a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic in Arlington, Virginia. Olivier Douliery / AFP.

NEW YORK, NY (AFP).- Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharmaceutical company Gilead Sciences by nearly $900 million, according to results released Wednesday by the drugmaker.

The medication, sold under the brand name Veklury and originally developed to treat Ebola, has been shown to shorten the recovery time for patients hospitalized with the new coronavirus.

Gilead reported a 17 percent jump in third-quarter revenues to $6.6 billion.

The company reported a profit of $360 million, compared with a loss of $1.2 billion in the year-ago period.

The US Food and Drug Administration last Thursday granted full approval to the antiviral drug remdesivir as a treatment for patients hospitalized with Covid-19, after conditional authorization was given in May.

Remdesivir, which is administered by an injection, was one of the first drugs to show relative promise in treating the virus, although its efficacy in reducing its mortality rate is unproven.

President Donald Trump, who tested positive for the coronavirus early in October, was treated with remdesivir -- among other drugs -- at a military hospital outside Washington.

Shares of Gilead fell 1.4 percent to 57.90 in after-hours trading.

© Agence France-Presse

Today's News

October 29, 2020

New system uses floor vibrations to detect building occupants

For the first time, scientists demonstrate self-repair mechanism in cells

Lighting a path to Planet Nine

Research tracks how pterosaurs mastered the primeval skies

Dull-colored birds don't see the world like bright birds do

How stem cells choose their careers

Gilead Sciences reports almost $900 mn in Q3 remdesivir sales

New smartwatch app alerts d/Deaf and hard-of-hearing users to birdsong, sirens and other desired sounds

A census of the soil microbiome

CUHK develops effective energy harvester breaking through the limitation of battery life of smart watches and Wristbands

Researchers found that commercially available wearables do not accurately monitor stress fracture risks

NASA's Perseverance rover is midway to Mars

Stanford researchers link poor memory to attention lapses and media multitasking

Increased risk of death in smoke impacted areas during and after the Hazelwood mine fire

University expands access to OMEGA laser with Energy Department's LaserNetUS initiative

Penn Medicine researchers receive $5.4 million grant to find genetic drivers of testicular cancer

'Fast' MRI detects breast cancers that 3-D mammograms may miss

AI helps molecular engineers design custom plastics


Editor & Publisher: Jose Villarreal
Art Director: Juan José Sepúlveda Ramírez

Tell a Friend
Dear User, please complete the form below in order to recommend the ResearchNews newsletter to someone you know.
Please complete all fields marked *.
Sending Mail
Sending Successful